On 21 August 2025, BioDlink (previously known as TOT BIOPHARM) announced that its Bevacizumab Injection, biosimilar to Roche/Genentech’s Avastin®, has received marketing approval from Indonesia’s National Agency of Drug and Food Control (BPOM).
This news comes just days after BioDlink’s 13 August 2025 announcement that its biosimilar bevacizumab received marketing approval from Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) and Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA).
BioDlink’s manufacturing facility has received GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia and Pakistan and its global licensee for the bevacizumab biosimilar in emerging markets, Kexing Biopharm, has initiated regulatory filings in 35 countries.